Stephen Griffin, PhD, has been appointed president of Cerus Endovascular effective immediately. Dr. Griffin had previously served as the company’s chief technology officer since joining in 2014 announced by the company today.

Sam J. Milstein, PhD, lead director of the company commented, “For the past four years, Stephen has been an integral part of the Cerus team, and it gives the Board great satisfaction to recognize his vast contributions through his promotion to president. In addition to inventing or co-inventing Cerus’s portfolio of interventional neuroradiology devices, including the Contour Neurovascular System™, as well as its intra-saccular coil assist neck bridge technology and microcatheters, Stephen has played a key role in their clinical advancement while also forging relationships with key opinion leaders and pursuing strategic collaborations.” He concluded, The Board looks forward to the continuity of Stephen’s leadership as Cerus works to bring its novel aneurysm treatments to market while creating significant value for its investors.”

“I am honored to accept the role of president of Cerus Endovascular at this important time in the company’s evolution,” replied Dr. Griffin. “We are working toward a number of important milestones this year, including CE Mark and FDA approval for our family of microcatheters, the first of which has been submitted for approval in the U.S. We are also working toward completion of CE Mark trial enrollment of the Contour Neurovascular System™, and the initiation of activities to support an investigational device exception (IDE) study of both the Contour Neurovascular System™ and the intra-saccular neck bridge device technology. We believe these technologies have the potential to significantly advance the field of aneurysm therapy, and we continue to work diligently to bring these treatment options to patients who need them.”

Prior to joining Cerus Endovascular, Dr. Griffin founded a medical device and technology consultancy, Griffin Biomedical, which counted Cerus Endovascular among its clients. Before that, he served as vice president of research and technology development at Covidien (which was acquired by Medtronic in 2015) and, before that, director of research and development at Nellix Endovascular. Prior to joining Nellix, he served as director of research and development at Cordis (a unit of J&J, which was sold to Cardinal Health in 2015). Earlier in his career, Dr. Griffin served in various research and development roles of increasing responsibility at Boston Scientific. He received his PhD and his BS in Materials Science from the University of Limerick.

The company also announced that Todd Derbin is no longer chief executive officer or chairman of the company or its U.S. subsidiary.